Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCyte BiotechPMCB -7.05%34 EV-to-OCF is 5.81 as of Aug. 10, 2026. GuruFocus rates PMCB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, PharmaCyte Biotech ranks worse than 80.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PharmaCyte Biotech's Enterprise Value is $-29.95 Mil.
PharmaCyte Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $-5.15 Mil. Therefore, PharmaCyte Biotech's EV-to-OCF for today is 5.81.
The historical rank and industry rank for PharmaCyte Biotech's EV-to-OCF or its related term are showing as below:
PMCB'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.7 Med: 0 Max: 5.81
Current: 5.81
During the past 13 years, the highest EV-to-OCF of PharmaCyte Biotech was 5.81. The lowest was 5.70. And the median was .
PMCB's EV-to-OCF is ranked worse than 80.85% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs PMCB: 5.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaCyte Biotech's PE Ratio (TTM) for today is calculated as:
PharmaCyte Biotech's share price for today is $0.546.
PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmaCyte Biotech EV-to-OCF Related Terms
PharmaCyte Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's EV-to-OCF falls into.
PharmaCyte Biotech's current Enterprise Value is $-29.95 Mil.
PharmaCyte Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a EV-to-OCF of 5.81 as of Aug. 10, 2026. Over the past decade, PharmaCyte Biotech's EV-to-OCF has ranged from 5.70 to 5.81. According to the industry distribution chart, PharmaCyte Biotech ranks #1136 out of 1405 companies in the Biotechnology industry, placing it in the top 80.9%.
Is PharmaCyte Biotech's EV-to-OCF too high?
PharmaCyte Biotech's current EV-to-OCF is 5.81. Over the past 10 years, this metric has ranged from a low of 5.70 to a high of 5.81. Based on the distribution chart, PharmaCyte Biotech ranks #1136 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's EV-to-OCF compare to NIKI and IMNN?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #1136 out of 1405 companies for EV-to-OCF. This places PharmaCyte Biotech in the lower half of its industry. Historically, PharmaCyte Biotech's own EV-to-OCF has ranged from 5.70 to 5.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. PharmaCyte Biotech's current EV-to-OCF is 5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current EV-to-OCF of 5.81. The current EV-to-OCF is 5.81. PharmaCyte Biotech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current EV-to-OCF is 5.81 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
34GF Score
Get the complete analysis for PMCB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
